Surmodics Inc

Análisis de la acción Surmodics Inc (SRDX)

$42.980

+0.150 (+0.35%)Al cierre

Loading chart…
High
43.005
Open
42.870
VWAP
42.61
Vol
5.34M
Mkt Cap
598.49M
Low
41.850
Amount
227.66M
EV/EBITDA, TTM
0.00

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Analyst Ratings (4)

Buy
2 Buy
2 Hold
0 Sell
Current: 42.98
Mínimo
32.00
Promedio
Máximo
32.00

Barrington

2025-11-14

Precio objetivo

Underperform

Lake Street

2025-03-07

Precio objetivo

$43

Strong Buy

Needham

2025-01-30

Precio objetivo

Hold

Needham

2024-11-07

Precio objetivo

Hold

Needham

2024-08-05

Precio objetivo

Hold

Métricas de valoración

The current forward P/E ratio for Surmodics Inc (SRDX) is -116.16, compared to its 5-year average forward P/E of -64.26.

Forward P/E

Fair
5Y Average P/E
-64.26
Current P/E
-116.16
Sobrevalorada
-10.52
Infravalorada
-118.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.46
Current EV/EBITDA
0.00
Sobrevalorada
61.85
Infravalorada
-36.93

Forward P/S

Strongly Undervalued
5Y Average P/S
4.11
Current P/S
0.00
Sobrevalorada
5.23
Infravalorada
2.99

Alphio AI Price Scenarios for SRDX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SRDX

$29.29

Precio del escenario

B

Base

Base · 50%SRDX

$28.10

Precio del escenario

B

Bear

Bear · 25%SRDX

$24.26

Precio del escenario

Whales holding SRDX

O

ODDO BHF Asset Management SAS

+ HoldingSRDX

+2.45%

3M Return

Cronología de eventos

2025-11-17 (ET)

06:13:21

FTC Will Not Appeal Surmodics' Acquisition

2025-11-10 (ET)

20:07:56

Surmodics announces District Court's rejection of preliminary injunction request

2025-11-04 (ET)

07:44:44

Surmodics' Pounce Thrombectomy System Demonstrates Effectiveness in Limb Ischemia Research

2025-10-29 (ET)

16:49:46

Surmodics reveals findings from PROWL registry study

Noticias

SRDX FAQ — answered by Alphio AI

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

4 analysts cover SRDX: 2 rate it Buy, 2 Hold and 0 Sell.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis